Immunogenicity in pig-tailed macaques of poliovirus replicons expressing HIV-1 and SIV antigens and protection against SHIV-89.6P disease
- PMID: 14585346
- DOI: 10.1016/s0042-6822(03)00546-4
Immunogenicity in pig-tailed macaques of poliovirus replicons expressing HIV-1 and SIV antigens and protection against SHIV-89.6P disease
Abstract
In the search for an effective vaccine against the human immunodeficiency virus (HIV), novel ways to deliver viral antigens are being evaluated. One such approach is the use of nonreplicating viral vectors encoding HIV and/or SIV genes that are expressed after infection of host cells. Nonreplicating poliovirus vectors, termed replicons, that expressed HIV-1/HXB2 and SIVmac239 gag and various HIV-1 env genes from different clades were tested for immunogenicity and protective efficacy against intravenous challenge of pig-tailed macaques with SHIV-89.6P. To maximize both cellular and humoral immune responses, a prime-boost regimen was used. Initially, macaques were immunized four times over 35 weeks by either the intranasal and intrarectal or the intramuscular (im) route with mixtures of poliovirus replicons expressing HIV-1 gag and multiple env genes. Immunization with replicons alone induced both serum antibodies and lymphocyte proliferative responses. After boosting with purified Env protein, neutralizing antibodies to SHIV-89.6P were induced in four of five immunized animals. In a second experiment, four macaques were immunized im three times over 27 weeks with replicons expressing the SIVmac239 gag and HIV-1/HXB2 env genes. All immunized animals were then boosted twice with purified HIV-1-89.6 rgp140-Env and SIVmac239 p55-Gag proteins. Four control animals received only the two protein inoculations. Immunized and control animals were then challenged intravenously with the pathogenic SHIV-89.6P. After challenge the animals were monitored for virus isolation from peripheral blood mononuclear cells and plasma viremia and for changes in virus-specific antibody titers. Naïve pig-tailed macaques experienced rapid loss of CD4(+) T cells and died between 38 and 62 weeks after infection. In contrast, macaques immunized with replicons and proteins rapidly cleared plasma virus and did not experience sustained loss of CD4(+) lymphocytes. Furthermore, two of the four macaques that were immunized only with purified proteins maintained high viral burdens and lost greater than 95% of their CD4(+) lymphocytes within 2 to 4 weeks after challenge. Thus, poliovirus replicons expressing HIV-1 and SIV antigens were immunogenic in pig-tailed macaques and appeared to enhance the protective effects observed after administration of purified proteins alone.
Similar articles
-
Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.J Infect Dis. 2007 Apr 1;195(7):980-8. doi: 10.1086/512243. Epub 2007 Feb 20. J Infect Dis. 2007. PMID: 17330788
-
Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.J Virol. 2005 Oct;79(19):12321-31. doi: 10.1128/JVI.79.19.12321-12331.2005. J Virol. 2005. PMID: 16160159 Free PMC article.
-
Characterization of the expression and immunogenicity of poliovirus replicons that encode simian immunodeficiency virus SIVmac239 Gag or envelope SU proteins.AIDS Res Hum Retroviruses. 1997 Jan 1;13(1):53-62. doi: 10.1089/aid.1997.13.53. AIDS Res Hum Retroviruses. 1997. PMID: 8989427
-
Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector.Springer Semin Immunopathol. 2006 Nov;28(3):239-53. doi: 10.1007/s00281-006-0042-3. Epub 2006 Sep 15. Springer Semin Immunopathol. 2006. PMID: 16977404 Free PMC article. Review.
-
CD4+ T cell responses to simian immunodeficiency virus.Curr Top Microbiol Immunol. 1994;188:161-73. doi: 10.1007/978-3-642-78536-8_9. Curr Top Microbiol Immunol. 1994. PMID: 7924425 Review. No abstract available.
Cited by
-
Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid.Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18648-53. doi: 10.1073/pnas.0709198104. Epub 2007 Nov 13. Proc Natl Acad Sci U S A. 2007. PMID: 18000037 Free PMC article.
-
Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDS.Mol Ther Methods Clin Dev. 2016 Feb 24;3:16007. doi: 10.1038/mtm.2016.7. eCollection 2016. Mol Ther Methods Clin Dev. 2016. PMID: 26958575 Free PMC article.
-
Oral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses.PLoS One. 2010 Sep 2;5(9):e12499. doi: 10.1371/journal.pone.0012499. PLoS One. 2010. PMID: 20824074 Free PMC article.
-
Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins.J Virol. 2015 Nov 18;90(3):1682-6. doi: 10.1128/JVI.02847-15. Print 2016 Feb 1. J Virol. 2015. PMID: 26581986 Free PMC article.
-
Disparate effects of acute and chronic infection with SIVmac239 or SHIV-89.6P on macaque plasmacytoid dendritic cells.Virology. 2007 Sep 1;365(2):356-68. doi: 10.1016/j.virol.2007.03.055. Epub 2007 May 8. Virology. 2007. PMID: 17490699 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials